A pharma company runs the same product through a dozen systems, and each one names it differently. R&D records a substance one way while manufacturing labels the material another, and by the time regulatory files its version to the authority and commercial sells under yet another, four defensible records exist that don't match. Put together, they produce shipment holds and submissions that bounce back.
Pharma master data management is the work of making those records agree, and keeping them in agreement across every system that touches a product, a material, a supplier, or a substance. The job used to sit quietly in the back office, but it doesn't anymore.
Two regulatory programs turned data consistency from an internal preference into an audited requirement. AI raised the price of bad data at the same time. So the same discipline that companies kept deprioritizing for twenty years is now the thing standing between them and a failed inspection or a stalled model.
What Master Data Means In Pharma
Master data is the set of core records that many systems share and depend on. In pharma, the categories carry more regulatory weight per record than in most industries.
- Substance and product data.
The regulated identity of a medicine: its ingredients, strengths, and dose forms. This is the layer that ISO IDMP standardizes. - Material and supplier data.
Raw materials, packaging, approved manufacturing sites, certifications, and audit history, all attached to the vendor record rather than kept in a spreadsheet next to it. - Location and organization data.
Sites, warehouses, and the legal entities behind them, identified with GS1 Global Location Numbers so supply chain systems can exchange them cleanly. - Customer and stakeholder data.
Pharmacies, distributors, hospitals, and healthcare professionals, with the affiliations that drive compliant engagement. - Reference data.
The codes, units, and classifications, such as ATC codes and dosage form terms, that everything above is built from.
Get the reference layer wrong, and every record that points to it inherits the error. That is why pharmaceutical master data management usually starts at the bottom of this list, not the top.
Why Pharma Master Data Management Became A Compliance Problem
Two frameworks did most of the work here.
The first is ISO IDMP. The European Medicines Agency is rolling it out through its SPOR programme, built on four domains of master data: Substance, Product, Organisation, and Referential. The practical vehicle is the Product Management Service. EMA has set data enrichment for critical medicines by the end of 2025 and for non-critical products by the end of 2026, and it released the public PMS API in beta in June 2026, with a final version expected in early 2027.
IDMP turns a medicine's identity into structured data before it ever becomes a submission.
The detail that trips people up is the source of truth. EMA wants product composition data drawn from Module 3 of the registration dossier, not from local Summaries of Product Characteristics, which drift in their terminology from market to market. That is a master data mandate wearing a regulatory hat. If your substance and product records already disagree internally, you cannot enrich PMS from a clean base.
US-only companies are not exempt from the groundwork. The FDA has mapped several of its long-standing standards to the ISO IDMP family, including the Unique Ingredient Identifier and the National Drug Code, so companies filing only in the US inherit part of the structure through standards they already meet.
The second framework is the Drug Supply Chain Security Act. Signed in 2013 to keep counterfeit drugs out of the legitimate supply chain, it requires electronic, package-level traceability across manufacturers, wholesalers, and dispensers. The enhanced requirements took effect in late 2023, then a stabilization period pushed real enforcement back. The FDA then staggered the exemptions: manufacturers to May 2025, wholesale distributors to August 2025, and larger dispensers to November 2025.
Under DSCSA, T3 data now moves electronically through EPCIS. Paper, PDFs, and manual spreadsheets no longer count. And that is where master data does the quiet heavy lifting. An EPCIS message fails when the Global Location Numbers or product identifiers on each side don't match. The hardest part of the whole program was never the barcode. It was the fully interoperable exchange of data between partners, and only about three-quarters of surveyed manufacturers expected to send 100% of required serialized data by the deadline.
So both programs reduce to the same dependency. Consistent identifiers, consistent product data, consistent location and organization records. When those disagree across systems, submissions bounce, and shipments stall.
The money follows the same logic. Poor data quality costs organizations an average of $12.9 million a year, by Gartner's estimate, and it rarely arrives as one dramatic failure. It leaks out in small corrections everywhere.
Catching a bad record at entry costs about a dollar. Cleaning it later costs ten. Once it has spread through connected systems, it costs a hundred.
The Trends Reshaping Pharma Master Data In 2026
The goal has shifted. For years, the pitch was a single source of truth, meaning deduplicated records in one place. That is table stakes now.
By 2026, pharma MDM does more than build a single source of truth. It makes supply chain, serialization, and compliance decisions faster and more defensible.
AI moved data quality from a nice-to-have to a gate.
Gartner predicts that through 2026, organizations will abandon 60% of AI projects that lack AI-ready data, and that 63% of organizations either don't have or aren't sure they have the right data management practices for AI. A model trained on inconsistent product and supplier records amplifies the inconsistency at speed. The fix is unglamorous work with a long history: golden records, governance, and deduplication at the source.
Golden records got stricter.
Consolidating source-system records into one authoritative version now comes with survivorship rules, lineage, and versioning, so a steward can show a regulator how a value was derived and what it used to be. In a GxP environment, that history is not optional.
Distribution went real-time.
Nightly batch jobs are giving way to event-driven synchronization, where a corrected record propagates to connected systems as it changes rather than the next morning. Serialization and traceability push this hard, because a failed exchange needs fixing in hours, not overnight.
Deployment control still matters in regulated data.
On-premise and private cloud remain common in pharma, driven by data residency, validation effort, and audit control. Open-source and configurable platforms have made that control cheaper to keep.
Supply chains have become more partner-driven.
Manufacturers coordinate contract manufacturers, packaging sites, third-party logistics providers, and distributors, and much of the master data problem now lives at the edge, in how vendors get onboarded and how their data is validated on the way in.
The market reflects all of this. Master data management in healthcare and life sciences was worth around $1.63 billion in 2024 and is projected near $2.98 billion by 2033, and healthcare sits among the fastest-growing verticals for MDM overall.
What A Real Deployment Looks Like
Trends are easier to trust when you can see the mess they clean up. A useful example comes from Nahdi Medical Company, Saudi Arabia's largest pharmacy-led retailer, with more than 1,150 pharmacies across 140-plus cities in Saudi Arabia and the UAE and over 10,000 staff. Its catalog spans pharmaceuticals, health and wellness, beauty, and medical equipment, sold across an e-commerce site and a mobile app.
The problems it faced will look familiar to anyone managing pharma product data at scale. The legacy system couldn't scale and produced duplicate product versions for different regions, so the same item existed several times with slightly different data. Vendor onboarding was fragmented, with unclear roles and little visibility. Thousands of SKUs had to be translated from English to Arabic by hand, which was slow and error-prone. And keeping large volumes of product data in sync with the commerce platform in real time kept breaking.
The fix centralized product data as a single source of truth for both the English and Arabic sites, using a configurable platform (AtroPIM) to model the catalog. Vendors and internal teams worked in parallel through role-based workflows. Vendors uploaded data through Excel feeds that imported directly. Translation memory and glossary tools automated the English-to-Arabic localization. Only verified and approved records synced downstream to the store. The full write-up sits in the Nahdi case study.
The practical lessons carry over to regulated pharma data more than the retail setting suggests:
- Deduplicate at the source, not per channel.
Regional duplicates multiply every downstream error and every manual correction. - Put approval workflows and permissions in place before automation.
Automating an unclear process just produces bad data faster. - Enforce quality at entry.
Structured vendor feeds with validation beat cleaning records after they have already spread. - Treat localization as data.
Translation memory and glossaries keep terminology consistent across markets, which matters more when the terminology is regulated. - Sync only verified records.
A commerce site, a trading partner, or a regulator should never receive a draft.
None of these are exotic. They are the parts teams skip when a deadline is close, then pay for later.
Choosing MDM Software For Pharma
The market splits into two rough camps. Large suites such as Informatica, Oracle, SAP, Stibo Systems, and Reltio bring depth and pharma-specific accelerators. Configurable, open-source platforms such as AtroCore, which consolidates records from source systems into golden records and can model arbitrary master data types, bring a flexible data model, on-premise control, and lower licensing costs, in exchange for more configuration work. The right pick depends on your regulatory scope and integration reality, not the length of a feature list.
Whichever camp you lean toward, these criteria matter most for pharma:
- A configurable data model.
Every material and supplier carries regulatory detail: certifications, approved sites, audit history. The tool has to model that on the record, not force a side spreadsheet. - Golden-record consolidation with survivorship, lineage, and versioning.
You need to show how a value was derived and what changed. - Built-in data quality.
Validation, matching, deduplication, and enrichment, running as data enters rather than as a quarterly cleanup. - Workflow and role-based governance with audit trails.
GxP means proving who changed what, and when. - Integration that fits both batch and event-driven exchange.
REST API, file, and database transfer, plus support for GS1 identifiers and EPCIS where serialization is in scope. - Deployment control.
On-premise or private cloud where residency and validation constrain you.
Score tools against your own regulatory obligations and the systems you already run. A platform that models your data cleanly and syncs verified records reliably will outperform a longer feature list that fits your process badly.
The regulators already settled the question of whether master data is optional. What's left is a practical one. Can your records survive an audit and feed a model at the same time?